News and Treatment Updates
Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.
Graft Vs Host Prophylaxis With Posttransplant Cyclophosphamide Not Associated With Increased Infection Risk
Originally Published: 09/09/2021
Article Source: External Web Content
According to the results of a study presented at the Annual Meeting of the Society of Hematologic Oncology (SOHO), graft vs host disease (GVHD) prophylaxis with posttransplant cyclophosphamide (PTCy) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) does not appear to be associated with an increased risk in bacterial, viral, or fungal infections.
The investigators sought to characterize the incidence of pre-vaccination infections, including cytomegalovirus (CMV), herpes virus and BK-polyomavirus hemorrhagic cystitis, infection-related mortality, and predictive factors...
Life Expectancy Still Lower for Blood or Marrow Transplant Recipients
Originally Published: 09/09/2021
Article Source: External Web Content
While late mortality among recipients of allogeneic blood or marrow transplantation (BMT) has decreased over the past 4 decades, life expectancy among these patients remains shorter versus the U.S. population at large, a retrospective cohort study found.
Compared with the general population, transplant patients had an 8.8-fold higher risk for all-cause mortality. Overall, the life expectancy of patients who underwent BMT was 20.8% lower than expected, translating into 8.7 years of life lost, reported Smita Bhatia, MD, MPH, of the Institute for Cancer Outcomes and Survivorship at the...
News for You! Foundation Update Newsletter August 2021
Originally Published: 08/17/2021
Article Source: Foundation Update
Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals
Originally Published: 08/12/2021
Article Source: External Web Content
FDA NEWS RELEASE
Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals
Other fully vaccinated individuals do not need an additional vaccine dose right now
For Immediate Release:
August 12, 2021
Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) for both the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals, specifically, solid organ transplant recipients or those who are diagnosed with...
Major Health Care Professional Organizations Call for COVID-19 Vaccine Mandates for All Health Workers
Originally Published: 07/26/2021
Article Source: External Web Content
Groups include American Medical Association, American Nurses Association, American Academy of Pediatrics, Association of American Medical Colleges, and National Association for Home Care and Hospice
(July 26, 2021) - With COVID-19 case counts rising amid the spread of the Delta variant, more than 50 health care professional societies and organizations called for all health care employers to require their employees to be vaccinated against COVID-19 in a joint statement released today. These societies and organizations represent millions of workers throughout health and long-term care – from...
What's New? Foundation Update Newsletter July 2021
Originally Published: 07/20/2021
Article Source: Foundation Update
FDA approves belumosudil for chronic graft-versus-host disease
Originally Published: 07/16/2021
Article Source: External Web Content
On July 16, 2021, the Food and Drug Administration approved belumosudil (Rezurock, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Efficacy was evaluated in KD025-213 (NCT03640481), a randomized, open-label, multicenter dose-ranging trial that included 65 patients with chronic GVHD who were treated with belumosudil 200 mg taken orally once daily.
The main efficacy outcome measure was overall response rate (ORR) through...
MDS Update Q2 2021
Originally Published: 07/16/2021
Article Source: MDS Update
New target to prevent leukaemia in Down’s syndrome children
Originally Published: 07/16/2021
Article Source: External Web Content
Researchers have mapped for the first time how and where leukaemia develops in children with Down’s syndrome, it has been announced.
Researchers at the Princess Margaret Cancer Centre in Toronto, Canada, say their research could eventually help doctors prevent pre-leukaemia in children with Down’s syndrome, and even have potential to transform cancer care in other children.
Children with Down’s syndrome have a 150-fold increased risk of developing myeloid leukaemia in their first five years of life. However, the mechanism by which the extra copy of chromosome 21 leads to leukaemia was...
Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination
Originally Published: 07/15/2021
Article Source: External Web Content
Key Points
Severe exacerbation of underlying hematologic conditions can occur within 1 to 4 days after dose 2 of a 2-dose SARS-CoV-2 vaccine series.
A mild exacerbation after dose 1 and/or a history of vaccine-related adverse events may portend a more serious event after dose 2.
Abstract
A variety of autoimmune disorders have been reported after viral illnesses and specific vaccinations. Cases of de novo immune thrombocytopenia (ITP) have been reported after SARS-CoV-2 vaccination, although its effect on preexisting ITP has not been well characterized. In addition, although COVID-19 has been...